Category Archives: Global News Feed


Stem Cell Clinic > Global News Feed

Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference

By Global News Feed

LONDON, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, today announced that Theresa Heggie, Chief Executive Officer, will present at the Chardan Virtual 4th Annual Global Healthcare Conference on October 6 at 4:45pm EDT.

Link:
Freeline to participate in Chardan’s 4th Annual Genetic Medicines Conference

Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society…

By Global News Feed

--Final 12-Month Results from Phase II Trial to be Presented on October 1--LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that the Company will present novel data from its randomized, double-blind, Phase II HOPE-2 clinical trial with its lead investigational product, CAP-1002, in boys and young men with Duchenne muscular dystrophy (DMD).

Here is the original post:
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society...

Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.

By Global News Feed

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the addition of David J. Woodhouse, Ph.D., to the Board of Directors. Dr. Woodhouse currently serves as the chief executive officer and a director of NGM Biopharmaceuticals.

Read the original post:
Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.

BetterLife Provides Update on OTC Trading Activity

By Global News Feed

VANCOUVER, Sept. 23, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAT) an emerging biotech company, today announced that it has filed a Form 211 application with the Financial Industry Regulatory Authority (“FINRA”) to request permission to quote and resume trading of its securities on OTC Markets.

See the original post here:
BetterLife Provides Update on OTC Trading Activity

Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

By Global News Feed

ATLANTA, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19mg will be featured in over 20 papers and presentations during the EURETINA 2020 Virtual Congress, to be held on October 2-4, 2020.

Go here to see the original:
Alimera Sciences Announces Multiple Posters and Papers Highlighting the Durability of ILUVIEN® To Be Presented at the EURETINA 2020 Virtual Congress

Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

By Global News Feed

BASEL, Switzerland, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the launch of its “Forward for Health Equity” grant program. The program will provide funding to nonprofit healthcare organizations with innovative projects focused on improving healthcare access, with an initial focus on reducing racial disparities in prostate cancer and uterine fibroids in the U.S. Myovant will award as many as four grants of up to $50,000 each, for a total of $200,000.

Read the original post:
Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids

TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair

By Global News Feed

MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.

See original here:
TELA Bio Presents Additional Data from BRAVO Study of OviTex® for Ventral Hernia Repair

→←